CDH1 and breast cancer: As far as the selection criteria is concerned, among the 85 patients fulfilling the IGCLC criteria for HDGC [13], 10 (12%) proved to carry CDH1 pathogenic variants, while eight (9.4%) proved to carry pathogenic variants in other genes; of note, five of the latter patients showed pathogenic mutations in breast cancer genes (6%).